Abstract
Effective therapeutic interventions for the treatment and prevention of COVID-19 are urgently needed. A systematic review was conducted to identify clinical trials of pharmacological interventions for COVID-19 published between 1 December 2019 and 14 October 2020. Data regarding efficacy of interventions, in terms of mortality, hospitalisation and need for ventilation, were extracted from identified studies and synthesised qualitatively.
In total, 42 clinical trials were included. Interventions assessed included antiviral, mucolytic, anti-malarial, anti-inflammatory and immunomodulatory therapies. Some reductions in mortality, hospitalisation and need for ventilation were seen with interferons and remdesivir, particularly when administered early, and with the mucolytic drug, bromhexine. Most studies of lopinavir/ritonavir and hydroxychloroquine did not show significant efficacy over standard care/placebo. Dexamethasone significantly reduced mortality, hospitalisation and need for ventilation versus standard care, particularly in patients with severe disease. Evidence for other classes of interventions was limited. Many trials had a moderate-to-high risk of bias, particularly in terms of blinding; most were short-term; and some included low patient numbers.
This review highlights the need for well-designed clinical trials of therapeutic interventions for COVID-19 to increase the quality of available evidence. It also emphasises the importance of tailoring interventions to disease stage and severity for maximum efficacy.
Competing Interest Statement
Hana Müllerová and Ian Sabir are employees of and shareholders in AstraZeneca. Shehla Sheikh was an employee and shareholder of AstraZeneca at the time of manuscript preparation. Tobias Welte has received research grants from Deutsche Forschungsgemeinschaft (DFG), Bundesministeriums für Bildung und Forschung (BMBF), the European Union and the World Health Organization; fees for lectures from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Sanofi Aventis; and advisory board fees from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, GlaxoSmithKline, Janssens, Novartis, Pfizer, Roche and Sanofi Aventis. Lucy Ambrose and Gillian Sibbring are employees of Prime Global, which received funding from AstraZeneca for medical writing and editorial support for this manuscript and other projects.
Funding Statement
This study was funded by AstraZeneca PLC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No additional data available.
